TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Leqembi and Kisunla are FDA-approved antibodies for early symptomatic Alzheimer’s that bind to different forms of beta-amyloid and help the immune system clear it from the brain. Trials found modestly slower cognitive and functional decline, but the size of the everyday benefit and the drugs’ long-term impact remain debated; both carry risks including brain swelling and bleeding.
Leqembi and Kisunla, the two anti-amyloid monoclonal antibodies approved in the United States for Alzheimer’s, bind to different forms of beta-amyloid and help the immune system clear it from the brain. Clinical trials found that both drugs modestly slowed cognitive and functional decline in people with early symptomatic disease, but they do not restore lost memory, and the extent of benefit in daily life remains disputed.
Monoclonal antibodies are laboratory-made proteins designed to recognize specific targets. In Alzheimer’s, lecanemab, sold as Leqembi, binds to amyloid plaques and smaller beta-amyloid clusters called protofibrils. Donanemab, sold as Kisunla, primarily targets a modified form of beta-amyloid found in established plaques. By binding to these targets, both drugs help the immune system remove amyloid from the brain.
The drugs act on a feature of Alzheimer’s biology rather than directly replacing lost abilities. Amyloid plaques are a hallmark of the disease, but scientists are still working to establish how different forms of amyloid relate to cognitive decline. The source report says trials found substantial reductions in brain amyloid alongside modest slowing of clinical decline; removing more amyloid does not necessarily translate directly into greater cognitive benefit.
In Leqembi’s phase 3 trial, participants taking the drug declined about 27% more slowly over 18 months than those receiving placebo. In Kisunla’s phase 3 trial, participants across the overall study population had a 37% lower risk of progressing to the next clinical stage over 76 weeks than the placebo group. These are trial outcomes measured over specified periods, not estimates that patients regain function or stop progressing. Neither drug is a cure.
What Amyloid Removal Can—and Cannot—Do
The treatments offer an approach aimed at underlying disease biology, rather than symptoms alone, and may slow decline for some people treated during the early symptomatic stages. That makes timely diagnosis and confirming eligibility relevant for patients and clinicians weighing treatment. The reported trial effects, however, are modest, and their practical meaning for everyday independence is not settled.
There are also safety trade-offs. The April 2026 Cochrane review described in the source report pooled 17 trials involving more than 20,000 participants and concluded that average cognitive and functional benefits from anti-amyloid antibodies were too small to be clinically meaningful, while treatment increased risks of brain swelling and bleeding. Specialists disputed that assessment, including on the grounds that the review grouped newer drugs with older antibodies that did not substantially clear amyloid. The disagreement underscores that trial measurements and judgments about meaningful benefit are not the same thing.
monoclonal antibody Alzheimer's treatment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Two Drugs, Different Amyloid Targets
Leqembi received U.S. approval in July 2023, followed by Kisunla in 2024, according to the source report. Both were studied and approved for people in the earliest symptomatic stages of Alzheimer’s, rather than for all people with dementia or for those who have not developed symptoms. Their shared aim is amyloid clearance, but their preferred targets differ: Leqembi also binds smaller aggregates, while Kisunla primarily recognizes modified amyloid in established plaques.
Evidence outside controlled trials is developing. An Eisai-funded study of 177 people who took Leqembi for a year reported that 77% had not progressed to the next disease stage and 7% had moved from early Alzheimer’s to mild cognitive impairment. The study had no placebo group, so it cannot establish how much of the observed stability was caused by the drug. The source also describes 2026 real-world findings as suggestive, while cautioning that one or two years may be too short to measure the long-term effects of treatments for a slowly progressing disease.
“Existing approved drugs offer some benefit for some patients, but there remains a high unmet need for more effective treatments.”
— Edo Richard, senior author of the April 2026 Cochrane review and professor of neurology at Radboud University Medical Centre
As an affiliate, we earn on qualifying purchases.
How Much Benefit Patients Experience
It remains uncertain how much the trial differences translate into changes patients or caregivers would notice in daily life, and how durable any slowing may be over longer periods. Researchers are also still working to clarify how amyloid removal produces clinical effects and whether greater clearance reliably means greater benefit.
The source report describes a divide over how to interpret the evidence: the Cochrane review judged average benefits too small to be clinically meaningful, while some Alzheimer’s specialists argue newer antibodies provide meaningful, if modest, benefit. The Leqembi real-world study cannot resolve that debate because it lacked a placebo comparison. Individual outcomes, treatment risks and eligibility also require assessment by qualified clinicians; the source material does not provide full prescribing or monitoring guidance.
As an affiliate, we earn on qualifying purchases.
Longer Follow-Up and Real-World Evidence
Researchers will need longer follow-up and stronger real-world comparisons to assess whether the trial effects persist and how they affect daily function. Future studies may also help distinguish the effects of newer, higher-dose antibodies from older drugs and clarify the relationship between amyloid clearance and clinical outcomes.
For now, Leqembi and Kisunla remain treatments for a defined early stage of symptomatic Alzheimer’s, with potential benefit balanced against safety risks and uncertainty. Patients considering either drug should discuss eligibility, likely benefits and risks with a qualified health professional.
Alzheimer's disease early detection kits
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
How do Leqembi and Kisunla work?
Both are monoclonal antibodies that bind to forms of beta-amyloid and help the immune system clear it from the brain. Leqembi binds plaques and smaller aggregates called protofibrils; Kisunla primarily targets a modified form found in established plaques.
Do these drugs cure Alzheimer’s or restore lost memory?
No. The source report says neither drug is a cure or restores memory already lost. Trial evidence indicates they can modestly slow decline in people with early symptomatic Alzheimer’s.
How large were the trial effects?
In a phase 3 trial, Leqembi was associated with about 27% slower decline over 18 months than placebo. In Kisunla’s overall study population, participants had a 37% lower risk of progression to the next clinical stage over 76 weeks than the placebo group. These measures use different outcomes and time periods.
What risks and uncertainties are reported?
The April 2026 review cited in the source found increased risks of brain swelling and bleeding with anti-amyloid antibodies. Researchers and specialists disagree about whether average benefits are clinically meaningful, and longer-term effects remain uncertain.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
